Skip to content
Biodatica
Start free

Investigator

Bing Lim

THYMMUNE THERAPEUTICS, INC · funded by NIAID

Companies
2

Resolved onto their grants.

Grants
2

Federal awards on file.

Non-dilutive funding
$2.0M

Summed across those awards.

First award
Apr 15, 2022

On this record.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R44

    Development of a stem-cell derived thymic cell therapy to treat patients with athymia

    $1.0M

    Apr 15, 2022NIAIDTHYMMUNE THERAPEUTICS, INCNIH RePORTER · 11042805 (opens the source filing in a new tab)

  2. R44

    Development of a stem-cell derived thymic cell therapy to treat patients with athymia

    $1.0M

    Apr 15, 2022NIAIDTHYMMUNE THERAPEUTICS, INCNIH RePORTER · 11325820 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources